Status:

COMPLETED

Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases

Lead Sponsor:

National Institute of Environmental Health Sciences (NIEHS)

Conditions:

Autoimmune/Connective Tissue Diseases

Idiopathic Inflammatory Myopathies

Eligibility:

All Genders

2+ years

Brief Summary

This study will define the major genetic risk and protective factors for idiopathic inflammatory myopathies (IIM), a group of immune disorders affecting connective tissues such as muscles. It will als...

Detailed Description

Individuals who develop chronic harmful inflammation in association with self-reactive autoantibodies or T cells are said to have autoimmune diseases. The causes of these diseases are unknown but they...

Eligibility Criteria

Inclusion

  • Recruitment into the study is by invitation.
  • INCLUSION CRITERIA:
  • For the primary autoimmune and myositis study populations, children (less than 18 years of age) or adults (18 or more years of age) require a diagnosis of myositis or a related autoimmune or rheumatic disorder.
  • Family members need to be blood relatives of the proband with the diagnosis of an autoimmune disease.
  • Normal volunteers will be gender- and race-matched to a subset of autoimmune subjects as controls needed for specific studies.
  • Normal volunteers should be in good health, without a recognized systemic rheumatic disorder or other autoimmune disease, and should not be taking anti-inflammatory medicines, including nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.
  • For all subjects: ability of the subject or parents/legal guardians to provide informed consent to all aspects of the study after full protocol information is provided.
  • Patients enrolling in the MYOVISION national myositis patient registry were diagnosed with adult or juvenile DM, PM, IBM, or another form of myositis; resided within the United States or Canada at the time of diagnosis, and provided informed consent and completed the study questionnaires, either on paper or online. In the case of children \<18 years of age, the parent or legal guardian provided informed consent and completed the study questionnaires.
  • EXCLUSION CRITERIA:
  • Exclusion criteria for all protocol subjects:
  • medical illness that in the judgment of the investigators does not allow safe blood draws or other clinical evaluations needed for study participation;
  • cognitive impairment;
  • inability to give informed assent or consent.
  • Exclusion criteria for normal volunteers:
  • Recognized systemic rheumatic disorder or other autoimmune disease, history of cancer or taking anti-inflammatory medicines, including nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, severe trauma, infections or vaccinations within 8 weeks.
  • Exclusion criteria for patients in the MYOVISION national myositis patient registry were subjects with cognitive impairment and those unable to or unwilling to give informed consent,or failing to meet the inclusion criteria of the study.

Exclusion

    Key Trial Info

    Start Date :

    July 13 2005

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    719 Patients enrolled

    Trial Details

    Trial ID

    NCT00341679

    Start Date

    July 13 2005

    Last Update

    January 8 2026

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institute of Environmental Health Sciences (NIEHS), 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892